Reduction of cetrorelix dose in the antagonist multiple dose protocol and its impact on pregnancy rate and economic aspect. A randomized controlled study

Reduction of cetrorelix dose in the antagonist multiple dose protocol and its impact on pregnancy rate and economic aspect. A randomized controlled study - Reduction of cetrorelix dose and its impact on the pregnancy rate and economic aspects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027193

Enrollment

200

Registered

2017-09-01

Start date

2017-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recruitong

Interventions

Patients will receive 0.25 mg Cetrorelix in the pituitary down regulation through the period from the ovum reached 14 mm and till triggering day Patients will receive 0.125 mg cetrorelix in the pitui

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: women undergoing IVF/ICSI under 35 years old antagonist protocol PCO AMH > 1mIU

Exclusion criteria

Exclusion criteria: Severe endometriosis Previous IVF/ICSI failure Severe male factor

Design outcomes

Primary

Measure	Time frame
Number of ova retreived, quality of ooocytes	—

Secondary

Measure	Time frame
Number of embryos , clinical and ongoing pregnancy rates, and economic aspects of reducing cetrorelix dose.	—

Countries

Africa

Contacts

Public ContactAyman shehata dawood

Tanta university Obstetrics and gynecology

ayman.dawood@med.tanta.edu.eg+201020972067

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026